Data regarding the effects of thrombin and dabigatran-inhibited thrombin on protease-activated receptor 1 and activation of human atrial fibroblasts
Paola Altieri,
Maria Bertolotto,
Patrizia Fabbi,
Elena Sportelli,
Manrico Balbi,
Francesco Santini,
Claudio Brunelli,
Marco Canepa,
Fabrizio Montecucco,
Pietro Ameri
Affiliations
Paola Altieri
Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy
Maria Bertolotto
Department of Internal Medicine, University of Genova and First Clinic of Internal Medicine, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Patrizia Fabbi
Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy
Elena Sportelli
Department of Diagnostic and Surgical Sciences, University of Genova and Cardiovascular Surgery Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Manrico Balbi
Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Francesco Santini
Department of Diagnostic and Surgical Sciences, University of Genova and Cardiovascular Surgery Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Claudio Brunelli
Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy; Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Marco Canepa
Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Fabrizio Montecucco
Department of Internal Medicine, University of Genova and First Clinic of Internal Medicine, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Centre of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy
Pietro Ameri
Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy; Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Corresponding author at: Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy. Fax: +390103537990.
The data presented here are related to the research paper entitled “Thrombin induces protease-activated receptor 1 signaling and activation of human atrial fibroblasts and dabigatran prevents these effects” (Altieri et al., 2018) [1]. Data show that silencing of protease-activated receptor 1 (PAR1) prevents the activation of Fib isolated from atrial appendages of patients without atrial fibrillation (AF), as assessed by immunofluorescence for α-smooth muscle actin (αSMA) and Picro-Sirius red staining. Moreover, it is reported that primary atrial Fib obtained from two subjects with permanent AF express PAR1 and PAR2 and display enhanced αSMA immunoreactivity and collagen synthesis in response to thrombin, but not to dabigatran-bound thrombin, alike Fib from non-fibrillating atria.
